Floatz logo

Epirubicin

Hairy Cell Leukemia

Acerta Pharma BVPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hairy Cell Leukemia cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Joseph Tuscano
Phase 1/2B
(+)-VINCRISTINE
Acerta Pharma BV
Phase 1/2B
HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3
City of Hope Medical Center
Phase 2CCC
Acalabrutinib
Acerta Pharma BV
Phase 1/2CCC
Pembrolizumab
Acerta Pharma BV
Phase 1/2CCC

View all 11 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →